TRTong Rong

Tong Rong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tong Rong has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Huaying Mm Wang

    Department of Pathology, Affiliated Hospital of Jiujiang University, Jiujiang, Jiangxi 332000, China

    1 shared publication
  • Qisheng Tang

    Jiangxi Key Laboratory for Microscale Interdisciplinary Study, Institute for Advanced Study, Nanchang University, Nanchang, People’s Republic of China

    1 shared publication
  • Wendiao Zhang

    Jiangxi Key Laboratory for Microscale Interdisciplinary Study, Institute for Advanced Study, Nanchang University, Nanchang, People’s Republic of China

    1 shared publication
  • Yang Liu

    Jiangxi Key Laboratory for Microscale Interdisciplinary Study, Institute for Advanced Study, Nanchang University, Nanchang, People’s Republic of China

    1 shared publication
  • Yang Zhang

    Jiangxi Key Laboratory for Microscale Interdisciplinary Study, Institute for Advanced Study, Nanchang University, Nanchang, People’s Republic of China

    1 shared publication
  • Yong Chen

    Institute for Advanced Study, Nanchang University, Nanchang 330031, China

    1 shared publication

Latest Publications

  • Open Access

    Isolated cell-bound membrane vesicles (CBMVs) as a novel class of drug nanocarriers

    by Yang Zhang, Yang Liu, Wendiao Zhang, Qisheng Tang, Yun Zhou, Yuanfang Li, Tong Rong, Huaying Wang, Yong Chen

    Background: Cell-bound membrane vesicles (CBMVs) are a type of membrane vesicles different from the well-known extracellular vesicles (EVs). In recent years, the applications of EVs as drug delivery systems have been studied widely. A question may arise whether isolated CBMVs also have the possibility of being recruited as a drug delivery system or nanocarrier? Methods: To test the possibility, CBMVs were isolated/purified from the surfaces of cultured endothelial cells, loaded with a putative antitumor drug doxorubicin (Dox), and characterized. Subsequently, cellular experiments and animal experiments using mouse models were performed to determine the in vitro and in vivo antitumor effects of Dox-loaded CBMVs (Dox-CBMVs or Dox@CBMVs), respectively. Results: Both Dox-free and Dox-loaded CBMVs were globular-shaped and nanometer-sized with an average diameter of ~ 300–400 nm. Dox-CBMVs could be internalized by cells and could kill multiple types of cancer cells. The in vivo antitumor ability of Dox-CBMVs also was confirmed. Moreover, Quantifications of blood cells (white blood cells and platelets) and specific enzymes (aspartate aminotransferase and creatine kinase isoenzymes) showed that Dox-CBMVs had lower side effects compared with free Dox. Conclusions: The data show that the CBMV-entrapped Doxorubicin has the antitumor efficacy with lower side effects. This study provides evidence supporting the possibility of isolated cell-bound membrane vesicles as a novel drug nanocarrier.